Rociletinib is a third-generation EGFR inhibitor active in lung cancers with T790M, the
gatekeeper mutation underlying most first-generation EGFR drug resistance. We biopsied�…

Background Non–small-cell lung cancer (NSCLC) with a mutation in the gene encoding
epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but�…

Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell�…

Somatic, activating mutations in EGFR identify a significant minority of patients with non–
small cell lung cancer (NSCLC). Although these mutations are associated with an�…

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib are
effective therapies against mutant non-small cell lung cancers (NSCLCs). Treatment is�…

Introduction The genomic alterations driving resistance to third-generation EGFR tyrosine
kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy samples poses�…

Purpose: A secondary EGFR mutation, T790M, is the most common resistance mechanism
in EGFR-mutant adenocarcinomas that have progressed on erlotinib. Third-generation�…

Patients with non–small cell lung cancer (NSCLC) harboring activating mutations in the
epidermal growth factor receptor (EGFR) kinase domain tend to respond well to the tyrosine�…

Introduction In approximately 60% of patients with NSCLC who are receiving EGFR tyrosine
kinase inhibitors, resistance develops through the acquisition of EGFR T790M mutation. We�…

Importance Osimertinib mesylate is used globally to treatEGFR-mutant non–small cell lung
cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by theEGFRT790M�…